JP2017517507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517507A5 JP2017517507A5 JP2016568657A JP2016568657A JP2017517507A5 JP 2017517507 A5 JP2017517507 A5 JP 2017517507A5 JP 2016568657 A JP2016568657 A JP 2016568657A JP 2016568657 A JP2016568657 A JP 2016568657A JP 2017517507 A5 JP2017517507 A5 JP 2017517507A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- variable region
- chain variable
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 112
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 90
- 229940127121 immunoconjugate Drugs 0.000 claims description 60
- -1 benzodiazepine dimer compound Chemical class 0.000 claims description 49
- 231100000433 cytotoxic Toxicity 0.000 claims description 49
- 230000001472 cytotoxic effect Effects 0.000 claims description 49
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 45
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 44
- 239000012634 fragment Substances 0.000 claims description 34
- 150000001768 cations Chemical class 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 24
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 20
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 20
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 20
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 19
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 19
- 239000012472 biological sample Substances 0.000 claims description 15
- 239000000523 sample Substances 0.000 claims description 13
- 210000000130 stem cell Anatomy 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- GWEVSJHKQHAKNW-UHFFFAOYSA-N 4-[[1-(2,5-dioxopyrrolidin-1-yl)-2h-pyridin-2-yl]disulfanyl]-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1C=CC=CN1N1C(=O)CCC1=O GWEVSJHKQHAKNW-UHFFFAOYSA-N 0.000 claims description 9
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 claims description 9
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 claims description 9
- 210000001185 bone marrow Anatomy 0.000 claims description 9
- 230000030833 cell death Effects 0.000 claims description 9
- 210000005259 peripheral blood Anatomy 0.000 claims description 9
- 239000011886 peripheral blood Substances 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 4
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 230000000144 pharmacologic effect Effects 0.000 claims 3
- 208000019838 Blood disease Diseases 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000036457 multidrug resistance Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 23
- 0 CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC(*)[C@]3N4c5ccccc5C3)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@@](C3)N4c5c3cccc5)c2C4=O)c1)S Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC(*)[C@]3N4c5ccccc5C3)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@@](C3)N4c5c3cccc5)c2C4=O)c1)S 0.000 description 14
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 6
- JSHOVKSMJRQOGY-UHFFFAOYSA-N O=C(CCCSSc1ncccc1)ON(C(CC1)=O)C1=O Chemical compound O=C(CCCSSc1ncccc1)ON(C(CC1)=O)C1=O JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 6
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 6
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N OS(C(CCSSc1ccccn1)C(ON(C(CC1)=O)C1=O)=O)(=O)=O Chemical compound OS(C(CCSSc1ccccn1)C(ON(C(CC1)=O)C1=O)=O)(=O)=O FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 description 3
- DOKWDOLZCMETIJ-ZAQUEYBZSA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)S Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)S DOKWDOLZCMETIJ-ZAQUEYBZSA-N 0.000 description 2
- VEVCIXHNMIPJED-MGAVHJTQSA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)S Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)S VEVCIXHNMIPJED-MGAVHJTQSA-N 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- NJFZGSDCOLQLAD-CBYVCPMDSA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=CC3(C)N4c5ccccc5C3)c2C4=O)cc(COc(cc(c2c3)NC[C@H](Cc4ccccc44)N4C2=O)c3OC)c1)SSCCCC(NC(C)(C)C1CCCC1)=O Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=CC3(C)N4c5ccccc5C3)c2C4=O)cc(COc(cc(c2c3)NC[C@H](Cc4ccccc44)N4C2=O)c3OC)c1)SSCCCC(NC(C)(C)C1CCCC1)=O NJFZGSDCOLQLAD-CBYVCPMDSA-N 0.000 description 1
- IJZPSYGVMFYGJO-ORTKPCQYSA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)cc(COc(cc(c2c3)NC[C@H](Cc4ccccc44)N4C2=O)c3OC)c1)SSCCC(C(NC(C)(C)C1CCCC1)=O)S(O)(=O)=O Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)cc(COc(cc(c2c3)NC[C@H](Cc4ccccc44)N4C2=O)c3OC)c1)SSCCC(C(NC(C)(C)C1CCCC1)=O)S(O)(=O)=O IJZPSYGVMFYGJO-ORTKPCQYSA-N 0.000 description 1
- OCRAJZOPOBJAEN-GCOKTQCFSA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(cc(c2c3)NC#CC(Cc4ccccc44)N4C2=O)c3OC)c1)S Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(cc(c2c3)NC#CC(Cc4ccccc44)N4C2=O)c3OC)c1)S OCRAJZOPOBJAEN-GCOKTQCFSA-N 0.000 description 1
- GQGJQCFYSSWHRF-HYNIKSJISA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(cc(c2c3)NC[C@H](CC4=C5CCC=C4)N5C2=O)c3OC)c1)SSCCCC(NC(C)(C)C1CCC1)=O Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(cc(c2c3)NC[C@H](CC4=C5CCC=C4)N5C2=O)c3OC)c1)SSCCCC(NC(C)(C)C1CCC1)=O GQGJQCFYSSWHRF-HYNIKSJISA-N 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000003203 nucleic acid sequencing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001015P | 2014-05-20 | 2014-05-20 | |
| US62/001,015 | 2014-05-20 | ||
| US201462011456P | 2014-06-12 | 2014-06-12 | |
| US62/011,456 | 2014-06-12 | ||
| US201462075715P | 2014-11-05 | 2014-11-05 | |
| US62/075,715 | 2014-11-05 | ||
| PCT/US2015/031580 WO2015179400A2 (en) | 2014-05-20 | 2015-05-19 | Methods for characterizing and treating acute myeloid leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517507A JP2017517507A (ja) | 2017-06-29 |
| JP2017517507A5 true JP2017517507A5 (enExample) | 2018-07-05 |
Family
ID=54554957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568657A Pending JP2017517507A (ja) | 2014-05-20 | 2015-05-19 | 急性骨髄性白血病を特徴付け、治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170080102A1 (enExample) |
| EP (1) | EP3145542A4 (enExample) |
| JP (1) | JP2017517507A (enExample) |
| KR (1) | KR20170004003A (enExample) |
| CN (1) | CN106456762A (enExample) |
| AU (1) | AU2015264322A1 (enExample) |
| BR (1) | BR112016026730A2 (enExample) |
| CA (1) | CA2947602A1 (enExample) |
| IL (1) | IL248555A0 (enExample) |
| MA (1) | MA39885A (enExample) |
| RU (1) | RU2016147398A (enExample) |
| SG (1) | SG11201609357PA (enExample) |
| WO (1) | WO2015179400A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1578446T1 (sl) * | 2002-11-07 | 2015-07-31 | Immunogen, Inc. | Protitelesa proti-cd33 in metoda za zdravljenje akutne mieloidne levkemije z uporabo istega |
| SI3313884T1 (sl) | 2015-06-29 | 2021-04-30 | Immunogen, Inc. | Protitelesa proti CD123 ter njihovi konjugati in derivati |
| US11191771B2 (en) | 2016-06-09 | 2021-12-07 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors |
| KR20190107656A (ko) * | 2016-11-02 | 2019-09-20 | 이뮤노젠 아이엔씨 | 항체-약물 콘주게이트 및 parp 억제제로 병용 치료 |
| WO2018183494A1 (en) * | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
| EP3624839A4 (en) * | 2017-05-17 | 2021-06-16 | Immunogen, Inc. | DOSING PLANS FOR ANTI-CD33 IMMUNE CONJUGATES |
| TW201922294A (zh) * | 2017-10-31 | 2019-06-16 | 美商伊繆諾金公司 | 抗體-藥物結合物與阿糖胞苷之組合治療 |
| MX2020004910A (es) | 2017-11-29 | 2020-10-05 | Magenta Therapeutics Inc | Composiciones y métodos para el agotamiento de células cd5 +. |
| TW202003048A (zh) * | 2018-05-15 | 2020-01-16 | 美商伊繆諾金公司 | 用抗體-藥物偶聯物及flt3抑制劑之組合治療 |
| WO2020010262A1 (en) * | 2018-07-06 | 2020-01-09 | University Of Washington | High throughput drug screening of cancer stem cells |
| WO2020051013A2 (en) * | 2018-08-24 | 2020-03-12 | The Trustees Of Columbia University In The City Of New York | Anti-cd33 and nkg2d ligand chimeras for treatment of myeloid malignancies |
| US20220251192A1 (en) * | 2019-06-26 | 2022-08-11 | Memorial Sloan Kettering Cancer Center | Anti-cd33 antibodies for treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6007814A (en) * | 1992-06-15 | 1999-12-28 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof |
| SI1578446T1 (sl) * | 2002-11-07 | 2015-07-31 | Immunogen, Inc. | Protitelesa proti-cd33 in metoda za zdravljenje akutne mieloidne levkemije z uporabo istega |
| WO2010126552A1 (en) * | 2009-04-30 | 2010-11-04 | Immunogen, Inc. | Potent cell-binding agent drug conjugates |
| US20140148351A1 (en) * | 2010-09-30 | 2014-05-29 | The Board Of Trustees Of The Leland Stanford Junior University | Prediction of Clinical Outcome in Hematological Malignancies Using a Self-Renewal Expression Signature |
| WO2012112687A1 (en) * | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Methods of preparation of conjugates |
| US20120282282A1 (en) * | 2011-04-04 | 2012-11-08 | Immunogen, Inc. | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates |
-
2015
- 2015-05-19 BR BR112016026730A patent/BR112016026730A2/pt not_active IP Right Cessation
- 2015-05-19 EP EP15795831.5A patent/EP3145542A4/en not_active Withdrawn
- 2015-05-19 KR KR1020167035135A patent/KR20170004003A/ko not_active Withdrawn
- 2015-05-19 RU RU2016147398A patent/RU2016147398A/ru not_active Application Discontinuation
- 2015-05-19 MA MA039885A patent/MA39885A/fr unknown
- 2015-05-19 US US15/311,632 patent/US20170080102A1/en not_active Abandoned
- 2015-05-19 AU AU2015264322A patent/AU2015264322A1/en not_active Abandoned
- 2015-05-19 CA CA2947602A patent/CA2947602A1/en not_active Abandoned
- 2015-05-19 WO PCT/US2015/031580 patent/WO2015179400A2/en not_active Ceased
- 2015-05-19 JP JP2016568657A patent/JP2017517507A/ja active Pending
- 2015-05-19 CN CN201580026480.1A patent/CN106456762A/zh active Pending
- 2015-05-19 SG SG11201609357PA patent/SG11201609357PA/en unknown
-
2016
- 2016-10-27 IL IL248555A patent/IL248555A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017517507A5 (enExample) | ||
| JP7118073B2 (ja) | 抗ｔｉｍ－３抗体を用いてがんを処置する方法 | |
| CN110177806B (zh) | 与met结合的抗met抗体、双特异性抗原结合分子及其使用方法 | |
| RU2016147398A (ru) | Способы оценивания и лечения острого миелоидного лейкоза | |
| RU2756275C2 (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| JP6877357B2 (ja) | Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 | |
| JP5909442B2 (ja) | ヒト化ａｘｌ抗体 | |
| KR102007055B1 (ko) | Cd27l 항원 결합 단백질 | |
| JP2021008487A (ja) | 抗ｎｋｇ２ａ抗体を使用した治療計画 | |
| ES3034582T3 (en) | Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody | |
| JP6527132B2 (ja) | 肝臓がんの診断及び治療のための組成物及び方法 | |
| AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| ES2717908T3 (es) | Anticuerpos S100A4 y usos terapéuticos de los mismos | |
| US11225515B2 (en) | Macrophage stimulating protein receptor (or RON—recepteur d'Origine Nantais) antibodies and uses thereof | |
| US20140271644A1 (en) | Combination/adjuvant therapy for wt-1-positive disease | |
| JP2016500256A (ja) | Ｂｃｍａ抗原結合タンパク質 | |
| US12371507B2 (en) | CDCP1 antibodies and antibody drug conjugates | |
| JP2020502271A5 (enExample) | ||
| JP2016539083A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2012529281A5 (enExample) | ||
| JP2017501137A5 (enExample) | ||
| ES2728936T3 (es) | Anticuerpos dirigidos contra CDH19 para melanoma | |
| JP7402691B2 (ja) | 抗ｃｄ２５抗体薬物複合体による併用療法 | |
| JP2015503909A5 (enExample) |